DK3381933T3 - Muteiner af hngal og relaterede proteiner med affinitet til et givet mål - Google Patents
Muteiner af hngal og relaterede proteiner med affinitet til et givet mål Download PDFInfo
- Publication number
- DK3381933T3 DK3381933T3 DK18167640.4T DK18167640T DK3381933T3 DK 3381933 T3 DK3381933 T3 DK 3381933T3 DK 18167640 T DK18167640 T DK 18167640T DK 3381933 T3 DK3381933 T3 DK 3381933T3
- Authority
- DK
- Denmark
- Prior art keywords
- affinity
- related proteins
- given target
- hngal muteins
- hngal
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/081—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Optics & Photonics (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7517508P | 2008-06-24 | 2008-06-24 | |
| EP09769304.8A EP2313430B1 (en) | 2008-06-24 | 2009-06-24 | Muteins of hngal and related proteins with affinity for a given target |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3381933T3 true DK3381933T3 (da) | 2020-08-03 |
Family
ID=41256028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18167640.4T DK3381933T3 (da) | 2008-06-24 | 2009-06-24 | Muteiner af hngal og relaterede proteiner med affinitet til et givet mål |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8420051B2 (enExample) |
| EP (2) | EP3381933B1 (enExample) |
| JP (1) | JP5711118B2 (enExample) |
| AU (1) | AU2009264214B2 (enExample) |
| CA (1) | CA2729322C (enExample) |
| DK (1) | DK3381933T3 (enExample) |
| WO (1) | WO2009156456A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1877428B1 (en) | 2005-04-22 | 2011-03-16 | University of Washington | Cyanine- chlorotoxin conjugate and method for intra-operative visualization of cancer |
| CA2724384A1 (en) | 2008-05-15 | 2009-11-19 | Transmolecular, Inc. | Treatment of metastatic tumors |
| US8420051B2 (en) * | 2008-06-24 | 2013-04-16 | Technische Universitaet Meunchen | Muteins of hNGAL and related proteins with affinity for a given target |
| BR112012013662B1 (pt) | 2009-12-07 | 2022-08-02 | Pieris Pharmaceuticals Gmbh | Muteínas de lipocalina associada à gelatinase de neutrófilo humano (lcn2, hngal), seu uso e seus métodos de geração e produção, molécula de ácido nucleico, célula hospedeira, composição farmacêutica e kit de diagnóstico ou analítico |
| JP5858932B2 (ja) | 2010-02-04 | 2016-02-10 | モルフォテック， インコーポレイテッド | クロロトキシンポリペプチドおよびコンジュゲートならびにその使用 |
| ES2601182T3 (es) | 2010-05-11 | 2017-02-14 | Fred Hutchinson Cancer Research Center | Variantes de clorotoxina, conjugados y métodos para su utilización |
| JP2013529907A (ja) | 2010-05-24 | 2013-07-25 | ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク | Ｎｇａｌタンパク質変異体及びその使用 |
| AU2011290751B2 (en) * | 2010-08-16 | 2015-08-13 | Pieris Ag | Binding proteins for Hepcidin |
| CA2817779C (en) * | 2010-11-15 | 2019-02-19 | Pieris Pharmaceuticals Gmbh | Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3) |
| US9758554B2 (en) | 2012-01-31 | 2017-09-12 | Technische Universitaet Muenchen | Muteins of α1m lipocalin and method of production therefor |
| US20140122522A1 (en) * | 2012-10-26 | 2014-05-01 | Google Inc. | Method for providing users with help from their contacts while searching the web |
| EP2920202B1 (en) | 2012-11-19 | 2018-08-29 | Pieris Pharmaceuticals GmbH | Novel specific-binding polypeptides and uses thereof |
| EP2925337B1 (en) * | 2012-11-21 | 2019-07-03 | The Trustees of Columbia University in the City of New York | Mutant ngal proteins and uses thereof |
| SG11201504600UA (en) * | 2012-12-10 | 2015-07-30 | Hutchinson Fred Cancer Res | Methods for screening |
| US11559580B1 (en) | 2013-09-17 | 2023-01-24 | Blaze Bioscience, Inc. | Tissue-homing peptide conjugates and methods of use thereof |
| EP3102224B1 (en) | 2013-12-20 | 2019-02-20 | NephroGenesis, LLC. | Apparatuses for kidney dialysis and lipocalin protein for use in the prevention or treatment of uremia by dialysis |
| EP3145945B1 (en) | 2014-05-22 | 2020-07-15 | Pieris Pharmaceuticals GmbH | Novel specific-binding polypeptides and uses thereof |
| SG11201705278QA (en) | 2015-01-28 | 2017-07-28 | Pieris Pharmaceuticals Gmbh | Novel proteins specific for angiogenesis |
| EP3259282A1 (en) | 2015-02-18 | 2017-12-27 | Sanofi | Novel proteins specific for pyoverdine and pyochelin |
| PH12017501583B1 (en) | 2015-05-04 | 2023-01-20 | Pieris Pharmaceuticals Gmbh | Novel proteins specific for cd137 |
| RU2727165C2 (ru) * | 2015-05-04 | 2020-07-21 | ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ | Слитый полипептид с противораковой активностью |
| DK3298030T5 (en) | 2015-05-18 | 2024-10-07 | Pieris Pharmaceuticals Gmbh | Anti-cancerfusionspolypeptid |
| EP3298029A1 (en) | 2015-05-18 | 2018-03-28 | Pieris Pharmaceuticals GmbH | Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3) |
| EP3115371A1 (en) * | 2015-07-07 | 2017-01-11 | Sanofi | Fusion molecules |
| EP3115066A1 (en) | 2015-07-07 | 2017-01-11 | Technische Universität München | Novel psma-specific binding proteins |
| US10703810B2 (en) | 2015-11-30 | 2020-07-07 | Pieris Australia Pty Ltd. | Fusion polypeptides which bind vascular endothelial growth factor a (VEGF-A) and angiopoietin-2 (Ang-2) |
| TW201725212A (zh) * | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
| US12048732B2 (en) | 2016-04-15 | 2024-07-30 | Blaze Bioscience, Inc. | Methods of treating breast cancer |
| AU2017260274A1 (en) * | 2016-05-04 | 2018-11-01 | Navigo Proteins Gmbh | Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker |
| US11235076B2 (en) | 2016-08-29 | 2022-02-01 | Fred Hutchinson Cancer Research Center | Chelating platform for delivery of radionuclides |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5124471A (en) | 1990-03-26 | 1992-06-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Bifunctional dtpa-type ligand |
| US5756825A (en) | 1992-09-08 | 1998-05-26 | Safavy; Ahmad | Hydroxamic acid-based bifunctional chelating compounds |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| JP3839667B2 (ja) | 1998-06-08 | 2006-11-01 | エフ．ホフマン−ラ ロシュ アーゲー | 慢性Ｃ型肝炎の処置のためのＰｅｇ−ＩＮＦ−アルファ及びリバビリンの使用 |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| US7211395B2 (en) | 2001-03-09 | 2007-05-01 | Dyax Corp. | Serum albumin binding moieties |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| US7118915B2 (en) | 2001-09-27 | 2006-10-10 | Pieris Proteolab Ag | Muteins of apolipoprotein D |
| US7691970B2 (en) | 2003-08-25 | 2010-04-06 | Pieris Ag | Muteins of a bilin-binding protein with affinity for a given target |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| WO2006025975A1 (en) | 2004-07-26 | 2006-03-09 | Isoray Medical, Inc. | Method of separating and purifying yttrium-90 from strontium-90 |
| US7892827B2 (en) | 2004-11-26 | 2011-02-22 | Pieris Ag | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| AU2006294644A1 (en) | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
| US8420051B2 (en) * | 2008-06-24 | 2013-04-16 | Technische Universitaet Meunchen | Muteins of hNGAL and related proteins with affinity for a given target |
-
2009
- 2009-06-24 US US12/737,240 patent/US8420051B2/en active Active
- 2009-06-24 CA CA2729322A patent/CA2729322C/en active Active
- 2009-06-24 AU AU2009264214A patent/AU2009264214B2/en active Active
- 2009-06-24 DK DK18167640.4T patent/DK3381933T3/da active
- 2009-06-24 EP EP18167640.4A patent/EP3381933B1/en active Active
- 2009-06-24 EP EP09769304.8A patent/EP2313430B1/en active Active
- 2009-06-24 WO PCT/EP2009/057925 patent/WO2009156456A1/en not_active Ceased
- 2009-06-24 JP JP2011514065A patent/JP5711118B2/ja active Active
-
2013
- 2013-04-09 US US13/859,119 patent/US9040020B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011525354A (ja) | 2011-09-22 |
| WO2009156456A1 (en) | 2009-12-30 |
| AU2009264214A1 (en) | 2009-12-30 |
| EP2313430A1 (en) | 2011-04-27 |
| US8420051B2 (en) | 2013-04-16 |
| US20130316962A1 (en) | 2013-11-28 |
| EP3381933B1 (en) | 2020-06-03 |
| JP5711118B2 (ja) | 2015-04-30 |
| EP3381933A1 (en) | 2018-10-03 |
| US20110262353A1 (en) | 2011-10-27 |
| US9040020B2 (en) | 2015-05-26 |
| AU2009264214B2 (en) | 2013-06-06 |
| CA2729322C (en) | 2020-05-26 |
| CA2729322A1 (en) | 2009-12-30 |
| EP2313430B1 (en) | 2018-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2676967T3 (da) | Fremgangsmåder til behandling af inflammatoriske og autoimmune sygdomme med natalizumab | |
| DK3202779T3 (da) | Hgh polypeptider med langtidsvirkning og anvendelser deraf | |
| DK2102398T3 (da) | Fremgangsmåde til fremstilling af en ankelsok og ankelsok opnået derved | |
| DK2139987T5 (da) | Fremgangsmåder til proteinfremstilling med anti-senescens-forbindelser | |
| ATE524493T1 (de) | Exendin-fusionsproteine | |
| DK2235044T3 (da) | Nye polypeptider med bindingsaffinitet til HER2 | |
| DK3339445T3 (da) | Interleukin -13 bindende proteiner | |
| DK2147096T3 (da) | Modificerede faktor-VII-polypeptider og anvendelser deraf | |
| DK3081315T3 (da) | Fremgangsmåde og system til sortering af fødevarer | |
| BRPI0906722A2 (pt) | Métodos e composições usando polipeptídeos de fusão klotho-fgf | |
| DE602007011923D1 (de) | Hepatocytenwachstumsfaktor-(hgf-)bindungsproteine | |
| DK3118221T3 (da) | Proteiner | |
| DK2913344T3 (da) | Specifikke bindingsproteiner og anvendelser deraf | |
| DK2046819T3 (da) | Fremgangsmåder til forøgelse af secernering af polypeptider med biologisk aktivitet | |
| DK3067064T3 (da) | Modificerede rsv-f-proteiner og fremgangsmåder til anvendelse deraf | |
| DK2099823T4 (da) | Målbindingsmiddelvarianter og anvendelser deraf | |
| DK2222675T3 (da) | 5-anilinoimidazopyridiner og fremgangsmåder til deres anvendelse | |
| DK2046362T3 (da) | Formulering omfattende valleprotein og hydrolysater til forbedring af muskelrekuperation | |
| DK3092901T3 (da) | Quinolonanaloger og fremgangsmåder relateret dertil | |
| DK2135603T3 (da) | Sammensætninger og fremgangsmåder til øgning af insulinsensitivitet | |
| DK2252633T3 (da) | Anti-TrkA antistoffer og derivater deraf | |
| DK2990798T3 (da) | Muteiner af human lipocalin 2 (lcn2, hngal) med affinitet for et specifikt mål | |
| DK2170827T3 (da) | Indolin-2-oner og aza-indolin-2-oner | |
| DK2222314T3 (da) | Anvendelser og midler til opnåelse af bronchorelaxation | |
| DK2171053T3 (da) | Natriuretiske polypeptider |